Enocitabine (BioDeep_00000765992)

   


代谢物信息卡片


Enocitabine

化学式: C31H55N3O6 (565.409065)
中文名称: 依诺他滨
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCCCCCCCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)C2C(C(C(O2)CO)O)O
InChI: InChI=1S/C31H55N3O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27(36)32-26-22-23-34(31(39)33-26)30-29(38)28(37)25(24-35)40-30/h22-23,25,28-30,35,37-38H,2-21,24H2,1H3,(H,32,33,36,39)/t25-,28-,29+,30-/m1/s1

描述信息

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
D000970 - Antineoplastic Agents
Enocitabine is a nucleoside analog, and is a potent DNA replication inhibitor, and a DNA chain terminator. Enocitabine inhibits the replication of human cytomegalovirus. Enocitabine has antileukemic and antiviral activities[1][2][3].

同义名列表

1 个代谢物同义名

Enocitabine



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Hiroyuki Fujita, Sachiya Takemura, Rie Hyo, Masatsugu Tanaka, Hideyuki Koharazawa, Shin Fujisawa, Heiwa Kanamori, Yoshiaki Ishigatsubo. Pulmonary embolism and thrombotic thrombocytopenic purpura in acute promyelocytic leukemia treated with all-trans retinoic acid. Leukemia & lymphoma. 2003 Sep; 44(9):1627-9. doi: 10.3109/10428190309178790. [PMID: 14565670]
  • T Yamauchi, Y Kawai, N Goto, S Kishi, S Imamura, A Yoshida, Y Urasaki, T Fukushima, H Iwasaki, H Tsutani, M Masada, T Ueda. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia. Japanese journal of cancer research : Gann. 2001 Sep; 92(9):975-82. doi: 10.1111/j.1349-7006.2001.tb01188.x. [PMID: 11572766]
  • T Yamauchi, Y Kawai, S Kishi, N Goto, Y Urasaki, S Imamura, T Fukushima, A Yoshida, H Iwasaki, H Tsutani, M Masada, T Ueda. Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses. Japanese journal of cancer research : Gann. 2001 May; 92(5):546-53. doi: 10.1111/j.1349-7006.2001.tb01128.x. [PMID: 11376564]
  • T Yoshida, K Kobayashi, Y Okabe, H Okumura, S Matano, M Kanno, Y Takeda, S Ohtake, S Nakamura, T Matuda. Plasma and leukemic cell pharmacokinetics of high-dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute leukemia patients. Journal of clinical pharmacology. 1994 Jan; 34(1):52-9. doi: 10.1002/j.1552-4604.1994.tb03966.x. [PMID: 8132852]
  • H Okumura, S Nakamura, S Ohtake, T Yoshida, K Kobayashi, Y Okabe, S Matano, K Kyohda, T Matsuda. Hemolytic uremic syndrome developing during remission of acute myelomonocytic leukemia. American journal of hematology. 1993 Sep; 44(1):66-7. doi: 10.1002/ajh.2830440115. [PMID: 8342567]
  • M Okamoto, H Fujita. [Pharmacokinetic studies of dFdC (2',2'-difluorodeoxycytidine), ara-C and BH-AC (N4-behenoyl ara-C) in experimental animals]. Gan to kagaku ryoho. Cancer & chemotherapy. 1992 Apr; 19(4):439-44. doi: NULL. [PMID: 1558392]
  • F Kimura, Y Takemura, T Ohtsuki, H Mizukami, S Takagi, K Yamamoto, N Nagata, K Motoyoshi. Serial changes of the serum macrophage colony-stimulating factor level after cytoreductive chemotherapy. International journal of hematology. 1992 Apr; 55(2):147-55. doi: NULL. [PMID: 1511164]
  • K Kaito, M Kobayashi, T Katayama, S Ochiai, M Yoshida, H Masuoka, T Shimada, K Nishiwaki, A Saito, R Watanabe. [Pharmacokinetics of BHAC, VP-16 and Ara-C derived from BHAC in a hemodialysed patient with AMMoL]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 1991 Dec; 32(12):1558-63. doi: NULL. [PMID: 1779456]
  • K Nakamura, Y Eizuru, K Kumura, Y Minamishima. Antiviral effect of antileukemic drugs N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus. Journal of medical virology. 1990 Jun; 31(2):141-7. doi: 10.1002/jmv.1890310212. [PMID: 1696958]
  • T Noda, M Oku, Y Kiyozuka, M Maruyama, S Adachi, S Akada, Y Okamura, M Ichijo. [Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine after intraperitoneal administration]. Gan to kagaku ryoho. Cancer & chemotherapy. 1988 Oct; 15(10):2929-35. doi: NULL. [PMID: 3178241]
  • Y Takashima. Clinical use of intermediate to high dose of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in children with acute leukemia. Journal of clinical pharmacology. 1988 Apr; 28(4):356-62. doi: 10.1002/j.1552-4604.1988.tb03158.x. [PMID: 3164731]
  • I Takahashi, H Nakada. [Chemotherapeutic effects in hypoplastic leukemia]. Gan to kagaku ryoho. Cancer & chemotherapy. 1988 Apr; 15(4 Pt 2-2):1209-14. doi: NULL. [PMID: 3260089]
  • T Yoshida, S Nakamura, S Ohtake, K Ito, K Kobayashi, M Kanno, J Hirai, K Tachimori, T Matsuda. [Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine]. Gan to kagaku ryoho. Cancer & chemotherapy. 1987 Jun; 14(6 Pt 1):1820-4. doi: NULL. [PMID: 3592717]
  • I Takahashi, H Nakada, N Hayashi, N Sekito, T Inagaki, S Aoyama, K Nonaka, E Ohmoto, Y Kobayashi, K Uchida. [Low-dose 4N-behenoyl-1-beta-D-arabinofuranosylcytosine (BHAC) in the treatment of atypical leukemia]. Gan to kagaku ryoho. Cancer & chemotherapy. 1986 Sep; 13(9):2780-5. doi: NULL. [PMID: 3463249]
  • K Kimura, R Ohno, I Amaki, K Hattori, Y Hirota, A Hoshino, M Ichimaru, M Ito, I Kimura, T Maekawa. Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Medical oncology and tumor pharmacotherapy. 1986; 3(1):15-24. doi: NULL. [PMID: 3702507]
  • T Ueda, T Nakamura, S Ando, D Kagawa, M Sasada, H Uchino, I Johno, Y Akiyama. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia. Cancer research. 1983 Jul; 43(7):3412-6. doi: NULL. [PMID: 6850647]
  • T Nakamura, T Ueda. [Chemotherapy of the malignancies from the viewpoint of pharmacology and biochemistry of cytosine arabinoside (ara-C) and its derivatives]. Gan to kagaku ryoho. Cancer & chemotherapy. 1982 Aug; 9(8):1339-51. doi: NULL. [PMID: 6191711]
  • Y Makino, Y Matsubara, K Watanabe, M Hirobe. [The simultaneous determination of Ara-U and Ara-C, urinary metabolites of N4-behenoyl-1-beta-D-arabinofuranosylcytosine by mass fragmentography (author's transl)]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 1982 Jan; 102(1):49-55. doi: 10.1248/yakushi1947.102.1_49. [PMID: 7086638]
  • J Oh-ishi, T Kataoka, S Tsukagoshi, Y Sakurai, M Shibukawa, H Kobayashi. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance. Cancer research. 1981 Jun; 41(6):2501-6. doi: NULL. [PMID: 7237444]
  • S Toyoshima, M Fukuma, Y Seto, H Fujita, K Fukushima, H Tomioka, T Sakurai, Y Sugimoto, T Yagi, T Hoshino, T Sowa. In vivo distribution of 14C-labeled N4-behenoyl-1-beta-D-arabinofuranosylcytosine in mice. Gan. 1981 Feb; 72(1):19-29. doi: NULL. [PMID: 7274645]
  • K Yamada, K Kawashima, Y Kato, Y Morishima, M Tanimoto, R Ohno. Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 1980; 70(?):219-29. doi: 10.1007/978-3-642-81392-4_23. [PMID: 6766563]